|Systematic (IUPAC) name|
|ATC code||C10AX02 (WHO)|
|Molar mass||516.844 g/mol[[Script error: No such module "String".]]|
However, clinical trials were stopped after it was found that may lower HDL in patients with a previous history of heart disease.
Probucol was initially developed in the 1970s by a chemical company to maximize airplane tire longevity.
Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption . Probucol is a powerful antioxidant which inhibits the oxidation of cholesterol in LDLs; this slows the formation of foam cells, which contribute to atherosclerotic plaques.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|30px||This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it.|